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Background:Deletions in ITPR1, coding for the inositol-
triphosphate receptor type 1, have been recently identi-
fied in spinocerebellar ataxia type 15 (SCA15).
Objective: To determine the frequency and the pheno-
typical spectrum of SCA15.
Design: Taqman polymerase chain reaction (258 in-
dex cases) or single-nucleotide polymorphism genome-
wide genotyping (75 index cases).
Setting:A collaboration between the Centre de Recher-
che de l’Institut de Cerveau et de la Moelle Epinière of
the Salpeˆtrière Hospital (Paris, France) and the Molecu-
lar Genetics Unit of the National Institute of Aging
(Bethesda, Maryland).
Patients: Index cases of 333 families with autosomal
dominant cerebellar ataxia negative for CAG repeat ex-
pansions in coding exons.
Main Outcome Measures: Detection of ITPR1 copy
number alterations.
Results:A deletion of ITPR1was found in 6 of 333 fami-
lies (1.8%), corresponding to 13 patients with SCA15.
Age at onset ranged from 18 to 66 years (mean [SD] age,
35 [16] years). The symptom at onset was cerebellar gait
ataxia, except in 1 patientwith isolated upper limb tremor.
Although families were tested irrespective of their phe-
notype, patients with SCA15 had a homogeneous phe-
notype and were characterized by a slowly progressive
cerebellar ataxia. However, pyramidal signs (2 patients)
andmild cognitive problems (2 patients) were occasion-
ally present. Radiologic findings showed global or pre-
dominant vermian cerebellar atrophy in all patients.
Conclusions: In this series, ITPR1deletionswere rare and
accounted for approximately 1% of all autosomal domi-
nant cerebellar ataxias. The SCA15phenotypemostly con-
sists of a slowly progressive isolated cerebellar ataxia with
variable age at onset; an additional pyramidal syndromeand
problems in executive functions may be present.
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A UTOSOMAL DOMINANT CER-ebellar ataxias (ADCAs) area clinically and geneticallyheterogeneous group ofprogressive diseases char-
acterized by cerebellar degeneration, often
accompaniedbydegenerative changes in the
brainstem,basal ganglia, cerebral cortex, spi-
nal cord, and peripheral nervous sys-
tem.1-3 To date, 28 genetic loci have been
linked to ADCAs, and, among these, 18
geneshavebeen identified.However, theun-
derlying cause of disease inup to50%of pa-
tients with ADCAs remains unknown.2,4
Based on the molecular mechanism, 3
major ADCA classes are considered: the
so-called polyglutamine diseases, caused
by translatedCAG repeat expansions (spi-
nocerebellar ataxia [SCA] type 1, SCA2,
SCA3, SCA6, SCA7, SCA17, and denta-
torubral-pallidoluysian atrophy); ADCAs
due to repeat expansions falling outside
the coding region of the respective genes
(SCA8, SCA10, SCA12, and puratro-
phin); and ADCAs caused by conven-
tional mutations (SCA5, SCA11, SCA13,
SCA14, SCA20, SCA27, and SCA28).5
Recently, deletions in ITPR1, coding for
the inositol-triphosphate receptor type 1
(ITPR1), have been identified in SCA15.
Deletionswere found initially in 3 SCA15-
positive families and then in 2 Japanese
families previously thought to have a dis-
tinct disease (SCA16)6-8; a missense mu-
tation was identified in another Japanese
family.7 Therefore, SCA15 and SCA16 are
actually the same disease: any family with
an ITPR1mutation should be regarded as
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having SCA15, whereas SCA16 should become a “va-
cant SCA.”9
The phenotype in the 10 SCA15-positive families de-
scribed so far is that of an almost pure, slowly progres-
sive cerebellar ataxia. Brainmagnetic resonance imaging
(MRI) showedmarked, predominantly vermian, cerebel-
lar atrophy.10-13 We report genetic and clinical data from
6 families with 13 patients carrying ITPR1 deletions and
estimate the relative frequency of this genetic entity.
METHODS
This study was approved by the local bioethics committee (Co-
mite´ Consultatif pour la Protection des Personnes et la Recher-
che Biomedicale Paris-Necker).Written informed consent was
obtained from all participating members of the families before
blood samples were collected for DNA extraction. DNA was
stored in the DNA and Cell Bank at the Pitie´-Salpeˆtrière Hos-
pital in Paris.
PATIENTS
We screened for ITPR1 rearrangements in 333 unrelated in-
dex cases of ADCA.Age at onset ranged from2 to 70 years (mean
[SD] age, 43.7 [20] years). The study population included 86
index caseswith pure cerebellar ataxia, 243 patients with a com-
plex phenotype, and 4 individuals for whom the precise phe-
notype was not available.
Additional signs found in the index cases with compli-
cated ADCA included in this series were alteration of vibra-
tion sense (n=79), pyramidal syndrome (n=72), cognitive
impairment (n=72), dysphagia (n=55), electromyography-
confirmed polyneuropathy (n=35), abnormal movements
(n=26), ophthalmoplegia (n=25), parkinsonism (n=19), men-
tal retardation (n=12), macular alterations (n=5), and optic
atrophy (n=3). Most participants were of western European
origin (n=307).
CAGrepeat expansions in theSCA1, SCA2, SCA3, SCA6, SCA7,
SCA17, anddentatorubral-pallidoluysian atrophy (DRPLA) genes
were excluded in all patients; repeat expansions responsible for
SCA10 were excluded in 118 patients and for SCA12 in 243 pa-
tients. Also, SCA5was excluded in 232 individuals, SCA11 in 61,
SCA14 in 197, SCA13 in 202, and SCA28 in 238.
Individual 020 in family LYO-210 was initially referred as
clinically affected, but molecular analysis did not find a dele-
tion of ITPR1, despite identification of an ITPR1 deletion in af-
fected family members. This individual was subsequently re-
examined by one of us (C.M.) and was diagnosed as having a
generalized dystonic and hyperkinetic syndrome. Onset of dys-
tonic symptoms was at age 46 years. Neurologic examination
at age 60 years revealed orofacial dystonia with blepharo-
spasm and facial grimaces, limb dystonic postures, and incon-
stant hyperkinetic movements; except for mild difficulty in the
heel/knee task, no other signs of cerebellar involvement were
present, and the patient did not note gait disequilibrium or
speech difficulties. Brain MRI, performed 14 years after dis-
ease onset, showed a very mild cerebellar vermis atrophy. He
was treated with anticholinergic drugs and botulinum toxin in-
jections in the orbicular muscles.
DETECTION OF COPY NUMBER ALTERATIONS
AT THE ITPR1 LOCUS
Twodifferent techniqueswere applied to detect ITPR1 gene dos-
age anomalies. Two hundred fifty-eight index cases of families
for whichDNA from only 1 affectedmember was available were
analyzed using a Taqman assay and an ABI 7900HT (Applied
Biosystems, Foster City, California); gene dosage analyses were
performed for exon 10 using -globin as an endogenous ref-
erence gene, and positive results were confirmed using single
nucleotide polymorphism (SNP) chips as per the manufactur-
er’s protocol (Illumina 610-Quad; Illumina Inc, SanDiego, Cali-
fornia). Seventy-five index cases from families inwhich theDNA
of more than 1 affected member was available were analyzed
by genome-wide SNP genotyping6 using human genotyping
chips (CNV370-Quad v3.0; Illumina Inc). Segregation analy-
ses were performed using Taqman polymerase chain reaction
in all available family relatives of index patients found to be
carriers of ITPR1 copy number changes.
RESULTS
We found 6 index cases harboring an ITPR1 deletion. The
availability of additional patients in 4 families allowed
us to confirm cosegregation of the disease with the mu-
tation.We collected and studied 13 patients with SCA15
(Figure 1).
The size of the deletion was studied by direct obser-
vation of SNP intensities in BeadStudio (Illumina Inc):
it involved ITPR1 and the neighboring gene SUMF1 in
families EPI-21 (approximately 390 kilobase [kb]),
SAL-153 (approximately 420 kb), and MAR-588 (ap-
proximately 190 kb); it involved ITPR1 and the neigh-
boring genes SETMAR and SUMF1 in family BOR-279
(approximately 590 kb); it was limited to ITPR1 in fami-
lies LYO-210 (approximately 250 kb) and BOU-698 (ap-
proximately 220 kb) (eFigure; http://www.archneurol
.com).
The main clinical features of the 13 patients with
SCA15 are given in the Table. All the families were of
French origin. Age at onset ranged from 18 to 66 years
(mean [SD] age, 35 [16] years); disease duration ranged
from 3 to 43 years (mean [SD], 23 [13] years).
The main presenting symptom was cerebellar gait
ataxia (12 of 13 patients) that was associated with
upper limb postural tremor in 3 patients and with a
pyramidal syndrome in 1 patient; 1 patient presented
with isolated upper limb postural tremor. Almost all the
patients subsequently developed a global cerebellar syn-
drome with gait and limb ataxia (13 of 13), ocular
movement abnormalities (10 of 11), and dysarthria (11
of 12), which remains the main clinical finding at all
stages of the disease. Ocular abnormalities were homog-
enous and were characterized by horizontal gaze-
evoked nystagmus and saccadic pursuit; saccadic veloc-
ity was preserved. Four patients (BOR-279-1,
BOR-279-5, MAR-589-9, and MAR-589-11) reported an
intermittent diplopia that disappeared in the following
disease course in 3 patients. Postural tremor of the
upper limbs was variably associated with disease pro-
gression: of the 4 patients with upper limb tremor at
disease onset, only 2 still presented this sign at follow-
up; in 1 patient, upper limb tremor appeared in a later
stage of the disease. None of the patients had head
tremor or titubation.
In addition to cerebellar ataxia, pyramidal signs with
enhanced reflexes and the Babinski sign were observed
ARCH NEUROL /VOL 68 (NO. 5), MAY 2011 WWW.ARCHNEUROL.COM
638
©2011 American Medical Association. All rights reserved.
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/neur/7811/ on 06/07/2017
in the 2 patients from family LYO-210. Mild swallowing
difficulties were reported by 2 other patients more than
30 years after onset of the disease. Although the Mini-
Mental State Examination result was normal in 2 pa-
tients, it was slightly altered in 2 others (patients EPI-
21-2 and EPI-21-7), with a score of 26 of 30 and 27 of
30 at ages 68 and 50 years, respectively, more than 25
years after disease onset. Moreover, patient EPI-21-7 had
a low IQ using the Wechsler Adult Intelligence Scale
(global IQ=84, verbal IQ=79, and performance IQ=93),
and a further neuropsychological evaluation confirmed
slightly worsened executive and attentive problems. Only
1 patient had a formal electromyographic examination,
which had normal findings; in addition, none of the pa-
tients presented a deep sensory alteration or reduced or
abolished reflexes, indicative of posterior column or pe-
ripheral nerve involvement. No urinary symptoms or ex-
trapyramidal signs were found.
Progression of the disease was particularly slow, and
disease severity was onlymoderate inmost patients (dis-
ability score of 1-4 on a 1-7 scale); only the 2 patients
withmore than 40 years of disease duration needed help
to walk (disability score=4), but they were still ambu-
latory.
Brain MRI was available for 11 patients showing cer-
ebellar atrophy (Figure 2), with a predominant dorsal
vermis involvement in 2 patients (Figure 3). In 2 pa-
tients, only a brain computed tomographic scanwas avail-
able, showing cerebellar atrophy.
COMMENT
Spinocerebellar ataxia type 15 is a rare form of ADCA.
In this cohort of patients with ADCAs excluded for mu-
tations inmajor ADCA genes, the frequency of ITPR1 de-
letions is 1.8% (6 of 333), and it increases to 7.0% (6 of
86) considering the subgroup of families with pure cer-
ebellar ataxia or minimal additional signs. Considering
all ADCA cases and that known polyglutamine expan-
sions cause approximately 50% of the ADCAs, the fre-
quency of ITPR1 deletions decreases to approximately
0.9%. The frequency we found is similar to the 2.7%
recently reported in a series of 73 nonpolyglutamine
ADCA–positive families.12 In this latter study, ITPR1 gene
deletions were searched using the multiplex ligation–
dependent probe amplification test, whereas in the present
study, Taqman polymerase chain reaction was per-
formed in the main subgroup of patients, with amplifi-
cation limited to exon 10. An underestimation of SCA15
frequency could, therefore, have occurred because it is
plausible that deletion may not extend to exon 10; ac-
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Figure 1. Pedigree of the 6 families with spinocerebellar ataxia type 15. *DNA was available for genetic analysis.
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tually, in 1 of 6 families (family MAR-588) analyzed by
genome-wide SNP genotyping, the deletion terminated
at approximately exon 10 and failed to be detected by
Taqman polymerase chain reaction during segregation
analysis. Previous studies6-8,12 and the present genome-
wide SNP genotyping on 75 families show that, up to now,
large deletions almost constantly involve the first 10 ex-
ons of ITPR1. This rearrangement, predicted to involve
theN-terminal inositol triphosphate–binding domain, has
been, therefore, proposed as aminimal critical region for
SCA1512; however, the case of family MAR-588 shows
that careful attention should be taken in targeting it for
diagnostic analysis.
We did not search for point mutations in ITPR1, al-
though a Japanese family harboring a P1059L missense
mutation and an individual with a V494I missense mu-
tation have been described.7,12 In the Japanese family har-
boring a P1059L missense mutation, the mutation was
located in exon 25 (ITPR1 RefSeq AAB044947.2; Gen-
Bank) and involved themodulatory and transducing do-
main. In the individual with a V494I missense muta-
tion, the mutation was in exon 15 (ITPR1 RefSeq
NM_001099952; GenBank), involving the inositol tri-
phosphate–binding domain. Although in both cases the
amino acids were highly conserved and located in im-
portant functional domains, the pathogenicity of themu-
tations has not yet been formally proved with func-
tional studies.12,14
Because we have not performed fine mapping of the
breakpoints in the families described herein, it is diffi-
cult to comment on the mutational mechanism in these
patients. Using PipMaker, Hara et al7 compared the 1-Mb
genomic sequence surrounding SUMF1 and ITPR1 against
itself. Sequence analysis of the breakpoint junction of all
patients with SCA15 reported at that time showed that
distal breakpoints were scattered within an approxi-
mately 65-kb region and proximal breakpoints within an
approximately 223-kb region.6-8 Moreover, in none of
these families with SCA15 has significant homology been
observed when comparing the reference sequence at the
distal and proximal breakpoints. This suggests that non-
allelic homologous recombination is unlikely to be the
mechanism by which ITPR1mutations occur. However,
overlap of 2 to 5 nucleotides between distal and proxi-
mal junction sequences has been identified in these fami-
lies, suggesting that nonhomologous end joiningmay be
the mutational mechanism in SCA15 cases.7
Although age at onset is highly variable, penetrance
of SCA15mutations seems to be complete; further stud-
ies are necessary to confirm this observation for genetic
counseling. In this study, we chose to analyze a large co-
hort of patients with ADCAs irrespectively of their clini-
cal presentation. Despite this, the global clinical and ra-
diologic features of most patients with an ITPR1 deletion
were homogeneous and concordant with previous clini-
cal studies describing an almost pure cerebellar ataxia.
However, pyramidal involvement with the Babinski sign
was present in 2 patients, in 1 at the onset of disease; be-
causemilder pyramidal signswere also described in 3 pre-
viously reported SCA15 cases,10-13 they could be consid-
ered part of the clinical spectrum of the disease in a few
patients. On the contrary, peripheral neuropathy, pre-
viously reported in the SCA15-positive Japanese family
with a missense mutation,7,15 was not present in any of
the present patients. The occurrence of impairment of
cognitive functions, possibly present in 2 patients on the
Table. Clinical Characteristics of 13 Patients With ITPR1 Deletions
Variable
Family Frequency,
No./
Total No.aLYO-210 EPI-21 BOR-279 MAR-588 SAL-153 BOU-698
Patient No. /sex 14/M 16/M 2/M 5/F 7/M 11/F 12/M 1/F 5/M 9/F 11/M 5/M 9/M NA
Age at onset, y 48 66 25 20 23 40 18 32 19 48 35 35 36 35 (16)
Symptoms
at onset
Gait
ataxia,
stiffness
Gait
ataxia
Ataxia Gait
ataxia
Gait
ataxia
Gait
ataxia,
UL
tremor
Ataxia Gait
ataxia,
UL
tremor
Gait
ataxia,
UL
tremor
Ataxia Gait
ataxia
Ataxia UL
tremor
NA
Disease
duration, y
24 14 43 31 27 6 14 31 13 17 19 42 10 23 (13)
Disability scoreb ND 3 4 3 3 1 1 3 3 3 3 4 2 NA
Gait ataxia              13/13
Limb ataxia      −        12/13
Dysarthria     ND  −       11/12
Nystagmus ND H, GE   H, GE ND − H, GE H, GE H, GE H,GE H, GE H, GE 10/10
Saccadic pursuit ND ND  ND  ND −    −   7/9
Postural tremor ND UL ND ND ND UL ND − − ND ND ND UL 3/5
Swallowing
problems
ND −  ND ND ND −  − − − − − 2/9
Pyramidal signs   − − − − − − − − − − − 2/13
EMG ND ND ND N ND ND ND ND ND ND ND ND ND 0/1
MMSE ND ND 26/30 ND 27/30 ND ND 30/30 ND ND ND 30/30 ND NA
Cerebellar
atrophy, MRI
NDc Global Global Vermis Global Global Vermis Global Global Global Global Global NDc 11/11
Abbreviations: EMG, electromyography; GE, gaze evoked; H, horizontal; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; N, normal;
NA, not applicable; ND, not determined UL, upper limb; , present; −, absent.
aAge and disease duration are given as mean (SD).
bDisability was assessed on a 7-point scale: 1, minimal disability; 2, unable to run but full autonomy; 3, moderate disability when walking; 4, unilateral support
required to walk; 5, bilateral support required to walk; 6, wheelchair bound; and 7, bedridden.
cTwo patients had computed tomographic evidence of cerebellar atrophy.
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basis of Mini-Mental State Examination and Wechsler
Adult Intelligence Scale scores, was confirmed in 1 pa-
tient showing progressive alteration of executive func-
tions and was also recently reported in 2 other pa-
tients.14 We cannot, therefore, exclude possible mild
cognitive involvement in a few patients with SCA15.
In the present series, ocular involvement is discrete
and is characterized by the combination of gaze-evoked
nystagmus and saccadic pursuit. An alteration of the ves-
tibulo-ocular reflex has been reported in the original Aus-
tralian family with SCA15.10 The combination of these
ocular abnormalities points toward involvement of the
flocculus-paraflocculus regions and of the dorsal ver-
mis,16 which is in accord withMRI findings. Because dip-
lopia had mostly disappeared at the last follow-up visit
and was not associated with ophthalmoplegia, we con-
sidered it a subjective symptom due to a defect in stabi-
lizing retinal images and not a sign of involvement of ex-
tracerebellar structures.
The boundaries between a pure and a complex cer-
ebellar ataxia are not always simple to define. In SCA15,
although we and other researchers13 show that other
systems may be involved, this occurs in only a few
patients, and cerebellar involvement largely predomi-
nates at clinical and radiologic levels. Compared with
the constant and marked multisystemic involvement
occurring in most polyglutamine ADCAs, SCA15
appears as pure cerebellar ataxia, sometimes associated
with minimal extracerebellar signs. We did not find a
correlation between the clinical phenotype and the
extension of ITPR1 deletion or the involvement of dif-
ferent contiguous genes.
The radiologic findings of the present patients with
SCA15 were also homogeneous and showed cerebellar,
predominantly vermian, atrophywithout cortical or brain-
stem involvement. Serial MRIs were not performed, and
we could not determine the progression of cerebellar at-
rophy and its correlation with clinical findings.
The pathogenesis of ataxia due to ITPR1 deletions re-
mains to be elucidated. ITPR1 is highly expressed in Pur-
kinje cells andmediates Ca2 release from the endoplas-
mic reticulum in various neurons, including CA1, basal
ganglia, and thalamic and Purkinje neurons.17,18 Homo-
zygous Itpr1 knockout mice develop severe ataxia and
epilepsy and die early in development19,20; a similar but
less severe phenotype was found in the opt mouse, har-
boring a homozygous in-frame deletion of exons 43 and
44 of Itpr1,21 and in a mouse with a homozygous in-
frame deletion of 18 base pairs in exon 36.6 A further
mouse model, Itpr1 heterozygous knockout, presented
isolated late-onset mild ataxia.22 In these models, no ap-
parentmorphologic abnormalities were found. Note that
none of the individuals with SCA15 due to ITPR1 het-
erozygous mutations had epilepsy or abnormal electro-
encephalographic findings.
Evidence suggests that impairment of the inositol 1,4,5-
triphosphate pathway is implicated in the pathogenesis of
different types of ataxia. In 2 SCA1 mouse models, itpr1
wasamong theneuronal genesdownregulatedat averyearly
stage in pathogenesis, and this downregulation required
nuclear localization of the mutant ataxin-1.23 The ITPR1
seems to specifically interact also with the mutated form
of the proteins ataxin-324 and ataxin-2,25 causing SCA3 and
SCA2, respectively. Moreover, mutation in carbonic an-
hydrase–related protein 8, which inhibits the binding of
inositol triphosphate to the ITPR1, has been recently shown
to cause anautosomaldominant ataxia associatedwithmild
mental retardation and predisposition to quadrupedal gait
in humans.26
Recently, the ITPR1 receptor signaling cascadehas been
found to underlie the coincidence detection system inPur-
kinje cells, responsible for cerebellar plasticity; the dys-
function of this system has been proposed to be the uni-
fying feature of themany genes that cause cerebellar ataxia
A B
C D
Figure 2. Brain magnetic resonance images of patient BOR-279-1 at age 63
years. Sagittal T1-weighted images (A and B) show global cerebellar atrophy,
mainly involving cerebellar vermis; axial T2/fluid-attenuated inversion
recovery–weighted (C) and T2-weighted (D) images show involvement of
cerebellar hemispheres.
A B
C D
Figure 3. Brain magnetic resonance images of patient EPI-21-5 at age 51
years. Sagittal T1-weighted images show upper and dorsal cerebellar vermis
atrophy with sparing of the pons (A) and cerebellar hemispheres (B); axial
T1-weighted (C) and T2-weighted (D) images show relative sparing of
cerebellar hemispheres.
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and interactwith ITPR1.27Moreover, ITPR1 interactswith
the huntingtin protein, mutated in Huntington disease,
and it is, therefore, involved also in the pathogenesis of
nonataxic neurodegenerative diseases.28
In conclusion, SCA15due to deletion in the ITPR1 gene
is uncommon; the relevance of SCA15 due to ITPR1 point
mutations remains to be determined. Although the main
phenotype is a cerebellar ataxic syndrome associated with
severe cerebellar atrophy, as seen by brain MRI, pyrami-
dal signs andexecutivedysfunctionscanalsobe rarely found
and, therefore, should not be considered exclusion crite-
ria. Disease progression is slow, and age at onset is remark-
ably variable. Moreover, it will be interesting to better un-
derstand the pathogenic mechanism of ataxia due to
dysfunction of the ITPR1 pathway and cerebellar plastic-
ity and to seewhether other ataxiasmay also be due to im-
pairment of the same signaling cascade.
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Announcement
Trial Registration Required. As a member of the Inter-
national Committee ofMedical Journal Editors (ICMJE),
Archives of Neurology will require, as a condition of con-
sideration for publication, registration of all trials in a pub-
lic trials registry (such as http://ClinicalTrials.gov). Trials
must be registered at or before the onset of patient en-
rollment. The trial registration number should be sup-
plied at the time of submission.
For details about this new policy, and for information
on how the ICMJE defines a clinical trial, see the edito-
rials by DeAngelis et al in the September 8, 2004 (2004;
292:1363-1364) and June 15, 2005 (2005;293:2927-
2929) issues of JAMA. Also see the Instructions toAuthors
on our Web site: www.archneurol.com.
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